Sienna Biopharmaceuticals Stock Forecast, Price & News

-0.01 (-26.61 %)
(As of 04/14/2021 02:59 PM ET)
Today's Range
Now: $0.02
50-Day Range
MA: $0.03
52-Week Range
Now: $0.02
Volume1,165 shs
Average Volume135,679 shs
Market Capitalization$549,408.00
P/E RatioN/A
Dividend YieldN/A
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
Sienna Biopharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$549,408.00
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.50 out of 5 stars

Medical Sector

1572nd out of 2,019 stocks

Pharmaceutical Preparations Industry

663rd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.01 (-26.61 %)
(As of 04/14/2021 02:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNNAQ News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNAQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) Frequently Asked Questions

What stocks does MarketBeat like better than Sienna Biopharmaceuticals?

Wall Street analysts have given Sienna Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sienna Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the following people:
  • Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 56, Pay $762k)
  • Mr. Timothy K. Andrews Esq., Gen. Counsel & Corp. Sec. (Age 42, Pay $446.1k)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 51)
  • Mr. Sean Andrews, VP of Investor Relations
  • Mr. Theodore Schwartz, Head of Global Strategic Marketing (Age 60)
  • Mr. Michael Attar, VP & Head of Corp. Devel.
  • Dr. David E. I. Pyott, Strategic Advisor to the Board and CEO (Age 68)

Who are some of Sienna Biopharmaceuticals' key competitors?

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "SNNAQ."

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNAQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNAQ stock can currently be purchased for approximately $0.02.

How much money does Sienna Biopharmaceuticals make?

Sienna Biopharmaceuticals has a market capitalization of $549,408.00.

How many employees does Sienna Biopharmaceuticals have?

Sienna Biopharmaceuticals employs 13 workers across the globe.

What is Sienna Biopharmaceuticals' official website?

The official website for Sienna Biopharmaceuticals is www.siennabio.com.

Where are Sienna Biopharmaceuticals' headquarters?

Sienna Biopharmaceuticals is headquartered at 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]

This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.